论文部分内容阅读
以随机公开对照试验比起对ＣＯＰＤ病人的支气管扩张作用及副作用．雾化吸入沙丁胺醇（５００μｇ）为Ａ组１６例；雾化吸入溴优异丙托品（５０μｇ）为Ｂ组１５例，雾化吸入沙丁胺醇（５０μｇ）合并异丙托品（５００μｇ）为Ｃ组１５例。结果：Ａ组１５分钟起效；Ｂ组６０分钟起效，其ＦＥＶ１（第一秒用力肺活量）及ＦＶＣ（用力肺活量）的最大改善率（２２．０％、２２．７％）与Ａ给（２１．５％、２３．２％）相比无差异（Ｐ＞０．０５），Ｃ组５、１５分钟ＦＥＶ１的改善率（８．７％、１３．０％）高于Ｂ组（０％、２％）；１８０、３６０分钟ＦＥＶ１的改善率为（２３．９％、１７．３％）高于Ａ组（１３．７％、５．８％）（Ｐ＜０．０５），ＦＶＣ与ＦＥＶ１的改变相近，三组均无严重的副反应。提示：ＣＯＰＤ患者雾化吸入异丙托品具有与沙丁胺醇相近的气道扩张作用．但起效慢．两者合用时，起效快，持续时间长，作用优于单药应用．
Randomized controlled trials comparing bronchodilation and side effects in patients with COPD. Inhalation of albuterol (500μg) was in group A (n = 16). Nebulization of bromodextrinase (50μg) in group B was 15 cases in group B, inhalation of albuterol (50μg) . Results: Group A started to function at 15 minutes and group B at 60 minutes. The maximum improvement rate (22.0%, 22.7%) of FEV1 (forced vital capacity in the first second) and FVC (forced vital capacity) 21.5%, 23.2%) (P> 0.05). The improvement rate of FEV1 at 5 and 15 minutes in group C (8.7% and 13.0%) was higher than that in group B (0% , 2%). The improvement rate of FEV1 at 180 and 360 minutes (23.9% and 17.3%) was higher than that of group A (13.7% and 5.8%, P <0.05) FEV1 changes are similar, no serious side effects in all three groups. Tip: Inhaled ipratropine in patients with COPD has similar airway dilation effect with salbutamol. But slow onset. When combined with the two, the rapid onset, long duration, the effect is better than single drug application.